Trial Profile
Investigation of Genetic Determinants of Capecitabine Toxicity.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic
- 26 Apr 2023 Planned End Date changed from 1 Jun 2022 to 15 May 2024.
- 26 Apr 2023 Planned primary completion date changed from 1 Jun 2018 to 15 May 2024.
- 18 May 2020 Planned End Date changed from 1 Jun 2020 to 1 Jun 2022.